Full-year 2017 guidance (Lonza standalone):
• Sales growth of high-single digits
• CORE EBITDA above CHF 1 billion
• Double-digit CORE EBIT growth significantly above sales growth
• CORE RONOA above the 21.5% achieved in 2016
Both Lonza segments, Pharma&Biotech and Specialty Ingredients, contributed to the strong third quarter with offerings along the healthcare continuum adding to the other growth drivers.
"Lonza sustained strong performance and growth of the company in the first nine months of the year, which proves the rationale behind our strategic direction," said Richard Ridinger, CEO of Lonza. "Our focus now is on the successful integration of Capsugel in order to realize the expected synergies and further boost our ambition to become the leading integrated service provider for the pharma and healthcare industries. The first three months of the integration have been promising. We have confirmed the close cultural fit while we've been bringing the first combined business opportunities to life."
Specialty Ingredients Segment
Specialty Ingredients experienced a solid Q3 2017 and performed as expected, contributing to the full-year guidance on a Lonza standalone basis. Growth drivers included the Hygiene and Preservation and the Consumer Health and Nutrition business, benefiting from high market demand and new, innovative product offerings in the fast-growing consumer products markets.
Capsugel Integration on Track
After the successful closing of the acquisition of Capsugel on July 5, 2017, the post-deal integration began immediately. Business and functional integration is on track with key managers from both Lonza and Capsugel leading the integration activities, the company said. Lonza is putting a strong focus on business continuity while the integration proceeds as planned.
Lonza and Capsugel employees are committed to the common path of offering high-quality products and services along the healthcare continuum – from ingredient sourcing to finished dosage form. First commercial synergies have already been identified with joint product offerings in consumer health and sports nutrition. Initial customer response to combined Lonza-Capsugel value proposition is positive.
In Q3 2017 Capsugel performed in line with expectations with particularly strong results in Consumer Health and Nutrition. Lonza confirms its positive outlook for Capsugel to deliver the expected synergies and growth targets. Combined financial figures will be reported with the full-year results 2017 in January 2018.
Pharma&Biotech saw another strong quarter in 2017 with Commercial Mammalian, Chemical Manufacturing and Clinical Development Services as key performance drivers. The hurricanes in the U.S. Southeast had no material impact on the company's overall performance as operational issues were resolved thanks to the efforts of the managers and employees in these regions.
Lonza also confirmed that its new cell and gene therapy manufacturing facility in Pearland, in the area of Houston, TX, which started construction in 2016, is nearing completion and is on schedule to start production in Q1 2018, despite the storms that hit the state of Texas in late August and early September.
Lonza Pharma&Biotech continued its momentum in Q3 2017; however, results are compared with an exceptionally strong Q3 2016. The outlook for Pharma&Biotech remains positive with ongoing customer demand, further potential to strengthen its commercial and operational excellence and its continued focus on innovation in products and services.